Efficacy and Safety of Sublingual Fentanyl Tablets in Treatment of Breakthrough Pain in Cancer Patients.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
17 Years and older (Child, Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Males or females 17 years of age or older
Stable cancer-related pain.
Are receiving a stable, fixed-schedule oral opioid regimen equivalent to 60 to 1000 mg of oral morphine per day or transdermal fentanyl therapy equivalent to 50 to 300 µg/h, and are on a stable dose of opioid medication for relief of breakthrough pain for at least 14 days prior to screening.
Experiencing 1-4 episodes of breakthrough pain per day.
Meet the criteria defined in the Eastern Cooperative Oncology Group (ECOG) Performance Status for Grade 0, 1, or 2.
Are pregnant or lactating.
Have uncontrolled or rapidly escalating pain.
Have moderate to severe ulcerative mucositis.
Have a cardiopulmonary disease that would increase the risk of administering potent opioids.
Have neurologic or psychologic disease that would compromise data collection
Have any clinically significant condition that would, in the investigator's opinion, preclude study participation.
Are currently taking monoamine oxidase inhibitors (MAOIs), or have taken MAOIs within 14 days prior to enrolling in the study.
Have received strontium 89 therapy within 60 days prior to entering the study.
Have received anti-neoplastic therapy within 2 weeks of study entry that, in the investigator's opinion, will influence assessment of breakthrough pain
Have received any investigational drug (non-approved) within 30 days prior to the first dose of study medication, or are scheduled to receive an investigational drug other than EN3267 during the course of the study.
Have hypersensitivities, allergies, or contraindications to fentanyl.
Have a significant prior history of substance abuse or alcohol abuse.
May have difficulty complying with the protocol, as assessed by the investigator.